CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Encapsulated fecal microbiota preparation +1 morebiological
Likely dose
30 capsules encapsulated fecal microbiota preparationAI-extracted
Key inclusion· 4
  • Age ≥18 years at enrollment
  • VRE-positive confirmed by stool culture within last 14 days
  • Able to swallow capsules
  • Able to provide written informed consent
Key exclusion· 17
  • Pregnant, lactating, or planning pregnancy during study
  • Unable or unwilling to swallow capsules
  • Active antibiotic-resistant bacteria or GI infection at enrollment
  • Antibiotic use within 48 hours of enrollment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03063437
NCT03063437Phase 2Completed

Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group Trial of Encapsulated Fecal Microbiota Transplantation for Vancomycin Resistant Enterococcus Decolonization

Microbiome Health Research Institute·interventional·Posted Feb 24, 2017·Updated Apr 13, 2020

In Brief

A Phase 2 clinical trial evaluating Encapsulated fecal microbiota preparation and Encapsulated placebo for Antibiotic Resistant Strain. Completed, enrolled 9 participants across 2 sites.

Detailed Summary

The objective of this study is to provide preliminary insight into the safety and efficacy of fecal microbiota transplantation (FMT) for the eradication of gastrointestinal carriage of vancomycin-resistant Enterococcus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 24, 2017
Enrollment StartAug 17, 2017
Primary CompletionSep 19, 2018
Study CompletionFeb 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.4 years ago

Interventions

Encapsulated fecal microbiota preparationbiological

30 capsules

Encapsulated placebobiological

30 capsules